Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced estimated EXPAREL® (bupivacaine liposome injectable suspension) and total revenues for the fourth quarter and full-year 2015. These estimates, which are unaudited, are based on management’s preliminary financial analysis.
“We are pleased with the strong finish to 2015 and the preliminary revenues that benefited from a solid fourth quarter—seasonally the strongest period of the year for procedure volumes,” said Dave Stack, chief executive officer and chairman of Pacira. “We are excited to have achieved a resolution with the FDA at the end of the quarter. In 2016, we will refocus our efforts to bolster the Pacira brand through targeted clinical studies, strategic commercial initiatives, and healthcare provider and patient-focused programs that seek to support the EXPAREL and DepoFoam® pipelines, and additional expansion opportunities.”
Fourth Quarter 2015
- EXPAREL revenues were an estimated $67.2 million, compared to $59.0 million in the fourth quarter of 2014.
- Total revenues were an estimated $69.4 million, compared to $61.8 million in the fourth quarter of 2014.
- EXPAREL revenues were an estimated $239.9 million, compared to $188.5 million in 2014.
- Total revenues were an estimated $249.0 million, compared to $197.7 million in 2014.
Pacira will provide final financial results and additional information on the fourth quarter and year-end 2015 performance in the earnings press release and conference call expected in late February. (Original Source)
Shares of Pacira closed yesterday at $75.12, up $0.65 or 0.87%. PCRX has a 1-year high of $121.95 and a 1-year low of $35.78. The stock’s 50-day moving average is $68.67 and its 200-day moving average is $59.92.
On the ratings front, Pacira has been the subject of a number of recent research reports. In a report issued on December 23, Wedbush analyst Liana Moussatos maintained a Buy rating on PCRX, with a price target of $123, which implies an upside of 63.7% from current levels. Separately, on December 18, Nomura’s Shibani Malhotra reiterated a Buy rating on the stock and has a price target of $100.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Liana Moussatos and Shibani Malhotra have a total average return of 17.9% and 22.8% respectively. Moussatos has a success rate of 44.5% and is ranked #64 out of 3630 analysts, while Malhotra has a success rate of 66.7% and is ranked #147.
Overall, one research analyst has assigned a Hold rating and 5 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $89.20 which is 18.7% above where the stock closed yesterday.
Pacira Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in the development, commercialization and manufacture of proprietary pharmaceutical products for use in hospitals and ambulatory surgery centers.